Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual Meeting
09 mai 2024 08h30 HE
|
Surrozen, Inc.
Surrozen Presents Data Demonstrating the Promise of Antibody Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at ARVO 2024
Surrozen Provides First Quarter 2024 Financial Results and Business Update
08 mai 2024 16h05 HE
|
Surrozen, Inc.
Surrozen Provides First Quarter 2024 Financial Results and Business Update
Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis
03 avr. 2024 08h40 HE
|
Surrozen, Inc.
Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis
Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043
01 avr. 2024 08h30 HE
|
Surrozen, Inc.
Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043
Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules
01 avr. 2024 08h30 HE
|
Surrozen, Inc.
Surrozen Announces up to $192.5 Million Private Placement of Securities
Priced At-the-Market Under Nasdaq Rules
Surrozen Provides Corporate Update on Clinical Programs
18 janv. 2024 08h30 HE
|
Surrozen, Inc.
Announces strategic prioritization of clinical programs to focus on development of SZN-043 for Alcohol-Associated Hepatitis SZN-043- Completed enrollment for the Phase 1a clinical trial in chronic...
Surrozen Provides Third Quarter 2023 Financial Results
08 nov. 2023 16h05 HE
|
Surrozen, Inc.
Expect to announce data from SZN-043 Phase 1a clinical trial in patients with chronic liver disease and in healthy volunteers in Q1 2024 Expect to announce data from SZN-1326 Phase 1a clinical...
Surrozen Provides Second Quarter 2023 Financial Results
09 août 2023 16h05 HE
|
Surrozen, Inc.
SZN-043 Phase 1a clinical trial in patients with chronic liver disease and in healthy volunteers continues to enroll with safety data expected by the end of 2023 SZN-1326 Phase 1a clinical trial in...
Surrozen Publishes Study in Nature Communications Demonstrating the Promise of a Fzd4 Wnt Antibody in Treating Ischemic Stroke
05 juin 2023 08h30 HE
|
Surrozen, Inc.
In a preclinical model of ischemic stroke, systemic delivery of a selective Fzd4 Wnt antibody strongly reduced blood-brain-barrier leakage, death of surrounding brain tissue, tissue swelling, while...
Surrozen Provides First Quarter 2023 Financial Results and Corporate and Pipeline Updates
10 mai 2023 16h05 HE
|
Surrozen, Inc.
Enrollment ongoing in SZN-043 Phase 1a clinical trial in people with chronic liver disease and in healthy volunteers with safety data expected by the end of 2023 Enrollment ongoing in SZN-1326 Phase...